SG11201501391YA - Bioconjugates comprising modified antigens and uses thereof - Google Patents
Bioconjugates comprising modified antigens and uses thereofInfo
- Publication number
- SG11201501391YA SG11201501391YA SG11201501391YA SG11201501391YA SG11201501391YA SG 11201501391Y A SG11201501391Y A SG 11201501391YA SG 11201501391Y A SG11201501391Y A SG 11201501391YA SG 11201501391Y A SG11201501391Y A SG 11201501391YA SG 11201501391Y A SG11201501391Y A SG 11201501391YA
- Authority
- SG
- Singapore
- Prior art keywords
- bioconjugates
- modified antigens
- antigens
- modified
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261698843P | 2012-09-10 | 2012-09-10 | |
PCT/EP2013/068737 WO2014037585A1 (en) | 2012-09-10 | 2013-09-10 | Bioconjugates comprising modified antigens and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201501391YA true SG11201501391YA (en) | 2015-03-30 |
Family
ID=49182230
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201501391YA SG11201501391YA (en) | 2012-09-10 | 2013-09-10 | Bioconjugates comprising modified antigens and uses thereof |
Country Status (12)
Country | Link |
---|---|
US (1) | US20150238596A1 (en) |
EP (1) | EP2892566A1 (en) |
JP (1) | JP2015529214A (en) |
KR (1) | KR20150054800A (en) |
CN (1) | CN104902931A (en) |
AU (1) | AU2013311534A1 (en) |
BR (1) | BR112015004817A2 (en) |
CA (1) | CA2883000A1 (en) |
HK (1) | HK1212249A1 (en) |
IL (1) | IL237522A0 (en) |
SG (1) | SG11201501391YA (en) |
WO (1) | WO2014037585A1 (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2019001795A (en) | 2013-01-17 | 2022-07-26 | X4 Pharmaceuticals Austria Gmbh | Mdr e. coli specific antibody. |
CA2926523C (en) | 2013-10-11 | 2023-09-26 | Glycovaxyn Ag | Methods of host cell modification |
AU2015220723C1 (en) | 2014-02-24 | 2018-04-05 | Glaxosmithkline Biologicals Sa | Novel polysaccharide and uses thereof |
LT3131577T (en) * | 2014-04-17 | 2020-07-27 | Glaxosmithkline Biologicals S.A. | Modified host cells and uses thereof |
CA2956188A1 (en) | 2014-08-08 | 2016-02-11 | Glycovaxyn Ag | Modified host cells for use in bioconjugate production |
TWI715617B (en) * | 2015-08-24 | 2021-01-11 | 比利時商葛蘭素史密斯克藍生物品公司 | Methods and compositions for immune protection against extra-intestinal pathogenic e. coli |
GB201610599D0 (en) | 2016-06-17 | 2016-08-03 | Glaxosmithkline Biologicals Sa | Immunogenic Composition |
AR109621A1 (en) | 2016-10-24 | 2018-12-26 | Janssen Pharmaceuticals Inc | FORMULATIONS OF VACCINES AGAINST GLUCOCONJUGADOS OF EXPEC |
CN107151270B (en) * | 2017-03-22 | 2018-07-31 | 武汉博沃生物科技有限公司 | Recombinate Δ fHbp-NadA fusion protein carriers and its preparation method and application |
GB201721576D0 (en) | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | Hla antigens and glycoconjugates thereof |
GB201721582D0 (en) | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | S aureus antigens and immunogenic compositions |
CN110652585B (en) * | 2018-10-26 | 2023-05-26 | 武汉博沃生物科技有限公司 | Polysaccharide-protein conjugate immune preparation and application thereof |
JP2022513458A (en) | 2018-12-12 | 2022-02-08 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Modified carrier protein for O-linked glycosylation |
AU2020205718A1 (en) * | 2019-01-11 | 2021-08-05 | Cornell University | Bioconjugate vaccines' synthesis in prokaryotic cell lysates |
KR102574882B1 (en) | 2019-03-18 | 2023-09-04 | 얀센 파마슈티칼즈, 인코포레이티드 | Methods for producing bioconjugates of E. coli O-antigen polysaccharides, compositions thereof and methods of use thereof |
JP7370391B2 (en) | 2019-03-18 | 2023-10-27 | ヤンセン ファーマシューティカルズ,インコーポレーテッド | Bioconjugate of Escherichia coli O antigen polysaccharide, its production method and its use method |
EP3757217A1 (en) | 2019-06-27 | 2020-12-30 | GlaxoSmithKline Biologicals S.A. | Methods for protein purification |
EP3770269A1 (en) | 2019-07-23 | 2021-01-27 | GlaxoSmithKline Biologicals S.A. | Quantification of bioconjugate glycosylation |
EP3777884A1 (en) | 2019-08-15 | 2021-02-17 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
MX2022015734A (en) | 2020-06-25 | 2023-01-18 | Glaxosmithkline Biologicals Sa | Modified exotoxin a proteins. |
KR20230043157A (en) | 2020-09-17 | 2023-03-30 | 얀센 파마슈티칼즈, 인코포레이티드 | Polyvalent Vaccine Compositions and Uses Thereof |
WO2023118033A1 (en) | 2021-12-22 | 2023-06-29 | Glaxosmithkline Biologicals Sa | Vaccine |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
ES2193742T3 (en) | 1998-08-28 | 2003-11-01 | Glaxosmithkline Biolog Sa | VACCINE COMPOSITIONS CONTAINING SALMONELLA TYPHI. |
MX2007003292A (en) * | 2004-09-21 | 2007-09-07 | Sanofi Pasteur Inc | Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine. |
ATE539079T1 (en) | 2006-03-23 | 2012-01-15 | Novartis Ag | IMIDAZOCHINOXALINE COMPOUNDS AS IMMUNE MODULATORS |
EP2007765B1 (en) | 2006-03-23 | 2012-06-27 | Novartis AG | Immunopotentiating compounds |
LT2257307T (en) * | 2008-02-20 | 2018-08-10 | Glaxosmithkline Biologicals S.A. | Bioconjugates made from recombinant n-glycosylated proteins from procaryotic cells |
-
2013
- 2013-09-10 JP JP2015530447A patent/JP2015529214A/en active Pending
- 2013-09-10 KR KR1020157005934A patent/KR20150054800A/en not_active Application Discontinuation
- 2013-09-10 WO PCT/EP2013/068737 patent/WO2014037585A1/en active Application Filing
- 2013-09-10 US US14/426,496 patent/US20150238596A1/en not_active Abandoned
- 2013-09-10 SG SG11201501391YA patent/SG11201501391YA/en unknown
- 2013-09-10 EP EP13762784.0A patent/EP2892566A1/en not_active Withdrawn
- 2013-09-10 CA CA2883000A patent/CA2883000A1/en not_active Abandoned
- 2013-09-10 AU AU2013311534A patent/AU2013311534A1/en not_active Abandoned
- 2013-09-10 BR BR112015004817A patent/BR112015004817A2/en not_active IP Right Cessation
- 2013-09-10 CN CN201380058695.2A patent/CN104902931A/en active Pending
-
2015
- 2015-03-03 IL IL237522A patent/IL237522A0/en unknown
-
2016
- 2016-01-13 HK HK16100360.4A patent/HK1212249A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
BR112015004817A2 (en) | 2017-07-04 |
JP2015529214A (en) | 2015-10-05 |
KR20150054800A (en) | 2015-05-20 |
CA2883000A1 (en) | 2014-03-13 |
AU2013311534A1 (en) | 2015-03-12 |
US20150238596A1 (en) | 2015-08-27 |
IL237522A0 (en) | 2015-04-30 |
EP2892566A1 (en) | 2015-07-15 |
HK1212249A1 (en) | 2016-06-10 |
WO2014037585A1 (en) | 2014-03-13 |
CN104902931A (en) | 2015-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1212249A1 (en) | Bioconjugates comprising modified antigens and uses thereof | |
HK1211302A1 (en) | Asgpr antibodies and uses thereof asgpr | |
HK1214282A1 (en) | Anti-notch3 antibodies and antibody-drug conjugates -notch3 - | |
HK1207092A1 (en) | Anti-hla-b27 antibodies and uses thereof -hla-b27 | |
HRP20190358T1 (en) | Anti-asic1 antibodies and uses thereof | |
HK1207654A1 (en) | Modified antibody regions and uses thereof | |
HK1210714A1 (en) | Antibody formulations and uses thereof | |
EP2885318A4 (en) | Peptide-dendrimer conjugates and uses thereof | |
ZA201405554B (en) | Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof | |
ZA201501124B (en) | Trans-clomiphene formulations and uses thereof | |
HK1210809A1 (en) | Beta-hexosyl-transferases and uses thereof | |
EP2825548A4 (en) | Modified kisspeptin peptides and uses thereof | |
ZA201407309B (en) | Antigens and antigen combinations | |
GB201208372D0 (en) | Antibodies and uses thereof | |
GB201207385D0 (en) | Antigens and antigen combinations | |
GB201207383D0 (en) | Antigens and antigen combinations |